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Abstract
Signal transduction from G-protein coupled receptors to MAPK cascades through heterotrimeric G-proteins has been
described for many eukaryotic systems. One of the best-characterised examples is the yeast pheromone response pathway,
which is negatively regulated by AKR1. AKR1-like proteins are present in all eukaryotes and contain a DHHC domain and six
ankyrin repeats. Whilst the DHHC domain dependant S-acyl transferase (palmitoyl transferase) function of AKR1 is well
documented it is not known whether the ankyrin repeats are also required for this activity. Here we show that the ankyrin
repeats of AKR1 are required for full suppression of the yeast pheromone response pathway, by sequestration of the Gbc
dimer, and act independently of AKR1 S-acylation function. Importantly, the functions provided by the AKR1 ankyrin repeats
and DHHC domain are not required on the same molecule to fully restore WT phenotypes and function. We also show that
AKR1 molecules are S-acylated at locations other than the DHHC cysteine, increasing the abundance of AKR1 in the cell. Our
results have important consequences for studies of AKR1 function, including recent attempts to characterise S-acylation
enzymology and kinetics. Proteins similar to AKR1 are found in all eukaryotes and our results have broad implications for
future work on these proteins and the control of switching between Gbc regulated pathways.
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Introduction
Heterotrimeric G-protein signalling pathways are found
throughout eukaryotes and are involved in a wide range of signal
transduction events. Heterotrimeric G-proteins, comprising Ga,
Gb and Gc subunits, are activated by ligand bound G-protein
coupled receptors (GPCRs). This generally leads to dissociation of
Ga from the Gbc dimer, both of which are involved in distinct
signalling activities. Little is known about which proteins link
signalling from Gbc dimers to downstream effectors.
The mating pheromone response of Saccharomyces cerevisiae is one
of the best characterised GPCR pathways. Many proteins affecting
responses to mating pheromone have been identified and
characterised resulting in a broad knowledge base that is useful
for further dissection of GPCR pathways. AKR1 has long been
known to be a negative regulator of the mating pathway in S.
cerevisiae yet the mode of suppression is unknown. The gross
phenotypic defects of akr1D mutants have been proposed to be a
result of simultaneous activation of both vegetative and mating
pathways [1]. akr1D cells are defective for endocytosis of the a-
pheromone GPCR STE3 [2] as a result of YCK2 mis-localisation
[3] and show up-regulation of the STE20/STE11/STE7/FUS3
MAPK mating pathway due to increased Gbc activity [1] leading
to partial cell cycle arrest and activation of mating pathway
morphogenesis genes in the absence of mating pheromone. These
defects result in an abnormal phenotype during vegetative growth
where cells frequently form multiple buds, have over-elongated
buds and often fail to complete cytokinesis resulting in a multi-
nucleate cell mass with pseudohyphal characteristics. akr1D cells
are not however impaired in mating efficiency or up regulation of
the mating pathway in response to pheromone [1,4]. These data
demonstrate that AKR1 is responsible for suppressing basal Gbc
mediated mating pathway signalling in the absence of mating
pheromone, but does not prevent full mating pathway activation
once pheromone is detected [4].
AKR1 has more recently been demonstrated to be a Protein S-
acyl transferase (PAT), also known as a palmitoyl transferase, with a
diverse range of substrates including the casein kinases YCK1 and 2
[5], LCB4 [6], MEH1, SNA4, LSB6 as well as 3 proteins of
unknown function [7]. AKR1 is responsible for the addition of lipid
groups through thioester linkages (S-acylation) to promote or
increase the membrane association of the target protein [5]. YCK2
is anchored to the membrane by two S-acyl groups where it aids in
many cellular processes, including septin organisation to maintain
correct cell shape [8,9,10], and phosphorylates both STE3 [3] and
the FUR4 uracil permease [11] to promote their endocytosis. The
defects in YCK2 S-acylation and STE3 endocytosis are thought to
be major contributors to the akr1D phenotype [5,10].
AKR1 is an integral membrane protein and contains 6 ankyrin
repeats and a DHHC PAT domain [12], although in AKR1 the
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same domain architecture are found across all eukaryotes, with
typically one to two per genome. DHHC domain containing
proteins have been shown to be responsible for S-acyl transferase
activity across eukaryotes [5,13,14,15,16,17]. It is not known
however if, and how, the ankyrin repeats of the ankyrin repeat
containing subset of PATs contribute to S-acylation. Not all PATs
contain ankyrin repeats, indicating that ankyrin repeats may not
be required for all S-acylation events.
Using functional complementation assays of akr1D defects, in-
vivo S-acylation assays and protein-protein interaction assays we
show that both the DHHC PAT domain and the ankyrin repeats
of AKR1 independently contribute to the regulation of GPCR/
Gbc signalling. Our results also show that AKR1 molecules
regulate each other’s S-acylation at sites other than the DHYC
cysteine and this affects the levels of AKR1 protein in the cell. The
ankyrin repeats promote AKR1 mediated S-acylation of YCK2,
but also affect Gbc signalling by a separate route that does not
involve AKR1 S-acylation activity. Our results also have
important implications for studies of AKR1 and PAT function,
including recent attempts to characterise the enzymology and
kinetics of S-acylation.
Results
AKR1 molecules increase each other’s S-acylation at
site(s) other than the DHHC cysteine by a mechanism
that proceeds without the AKR1 ankyrin repeats and
affects the stability of the AKR1 protein
AKR1 encodes a DHHC Protein S-Acyl Transferase (PAT) and
published evidence suggests that PATs auto-S-acylate to form a
stable catalytic intermediate through a thioester bond [5,18]. The
majority of PATs, unlike AKR1, do not contain ankyrin repeats,
suggesting that ankyrin repeats are not essential for S-acylation
activity. We deleted the ankyrin repeats of AKR1 to produce
AKR1 DN (Figure S1) and show that this truncated protein is still
S-acylated when expressed in-vivo, suggesting that it retains the
ability to auto-S-acylate (Figure 1A). These results indicate that
AKR1 DN may be able to function as a PAT and the ankyrin
repeats are not essential for S-acyl group binding.
Several previous reports have suggested that the DHHC
cysteine of AKR1 is required for formation of a stably S-acylated
catalytic form, and this residue is believed to be essential for PAT
activity [5,16,19]. AKR1 C
500S, in which this cysteine is mutated
(Figure S1), does not form an S-acylated intermediate or act as a
PAT (Figure 1A) [5]. Figure 1A shows that although AKR1 C
500S
is not S-acylated when expressed in akr1D mutants [5] it is S-
acylated when co-expressed with AKR1 DN. These results show
that AKR1 molecules that do not have a DHHC cysteine can be
S-acylated, demonstrating that S-acylation of AKR1 can occur at
sites other than the DHHC cysteine. They also suggest that AKR1
molecules S-acylate each other in trans and demonstrates that
AKR1 DN is able to act as a PAT in-vivo. These results are
surprising because AKR1 monomers do not form a complex
detectable by either co-immunoprecipitation [12] or yeast-2-
hybrid assays designed for membrane proteins (Figure S2),
although negative effects on higher order structures in these
assays may have prevented detection of interactions, and cannot
be ruled out. To establish that our observations are not a
peculiarity of the AKR1 DN background we expressed epitope
tagged AKR1 C
500S in the WT background and again observed S-
acylation of AKR1 C
500S (Figure 1B).
AKR1 C
500S is detected at lower levels by western blot when
expressed in akr1D cells, where it is not S-acylated, compared to
WT cells or akr1D cells co-expressing AKR1 DN, in which AKR1
C
500S is S-acylated (Figure 1C). These results suggest a role for S-
acylation of AKR1 outside of the DHHC motif in maintaining the
Figure 1. AKR1 S-acylates itself in trans and this does not
require the ankyrin repeats. S-acylation assays of AKR1 variants
expressed in yeast were performed using the biotin switch method
whereby hydroxylamine is used to specifically cleave S-acyl groups
revealing sulfhydryls which are subsequently labelled with biotin.
Samples are then passed through a neutravidin column and S-acylation
state is assayed as a function of recovery by the column using
antibodies against the protein of interest. Negative controls substitute
Tris, which does not cleave S-acyl groups, for Hydroxylamine. +indicates
presence of hydroxylamine, 2indicates absence of hydroxylamine. EX –
S-acylated AKR1 variants detected by the biotin switch method, LC –
loading control to show the total amount of AKR1 variant (regardless of
S-acylation state) in each sample. (A) AKR1 is able to covalently bind
acyl groups (auto-S-acylate) and disruption of the DHHC domain by
introduction of the C
500S mutation abolishes this auto acylation. AKR1
DN maintains the ability to auto acylate and co-expression of AKR1 DN
and AKR1 C
500S leads to S-acylation of AKR1 C
500S (upper band in lane
marked with *). (B) S-acylation of AKR1 C
500S in trans occurs in a wild
type background. Expression of AKR1 C
500S in WT cells (AKR1 fully
functional) produces the same S-acylation of AKR1 C
500S in trans as co-
expression of AKR1 C
500S with AKR1 DNi nakr1D cells. (C) Western blot
showing that the total amount of AKR1 C
500S detected increases in
conditions where this protein is S-acylated in trans, suggesting that S-
acylation promotes AKR1 stability. Expression of AKR1 C
500S in WT cells
or co-expression in akr1D cells with AKR1 DN leads to higher levels of
AKR1 C
500S being detected than expression of AKR1 C
500S alone in
akr1D cells. LC – loading control: Histone H3.
doi:10.1371/journal.pone.0028799.g001
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expressing AKR1 C
500S alone should be thought of as not only
defective for S-acylation activity [5], but also as having reduced
levels of AKR1 protein and therefore the ankyrin repeats.
The DHHC domain of AKR1 S-acylates YCK2 in the
absence of the ankyrin repeats
Yeast lacking AKR1 are misshapen, with cells frequently
forming multiple or branched buds and failing to complete
cytokinesis [1,4]. These akr1D phenotypes are likely due to mis-
localisation of the type-I casein kinases YCK1 and 2 [5,10]. YCK2
is thought to phosphorylate STE3 at the plasma membrane
leading to STE3 endocytosis and reducing basal Gbc signalling
thereby contributing to mating pathway suppression in the
absence of pheromone. YCK2 is reliant upon dual S-acylation
by AKR1 for localisation to the plasma membrane and YCK2 is
not S-acylated and is mislocalised in akr1D cells and akr1D cells
expressing AKR1 C
500S [5,10] indicating a specific role for the
DHHC domain in S-acylation of YCK2. Figure 2 shows that
AKR1 DN is capable of acting as a PAT, but cells expressing
AKR1 DN S-acylate less over expressed GFP-YCK2 in-vivo than
cells expressing full-length AKR1 (approximately 3.2–5.6 fold
depending on the experiment, data standardized to input levels of
GFP-YCK2). Co-expression of AKR1 C
500S and AKR1 DN
promotes S-acylation of over expressed YCK2 to a significantly
greater extent (approximately 2.1–3.6 fold) than AKR1 DN alone
but still less than full length AKR1 (Figure 2). The reduction in
AKR1DN S-acylation efficiency towards GFP-YCK2 may be due
to the effects of overexpression of GFP-YCK2 from the GAL1
promoter as AKR1DN is able to S-acylate AKR C
500S expressed
from it’s native promoter to the same level as WT (Figure 1A, 1B).
Loss of the ankyrin repeats may also lead to a failure to form a full
or stable YCK2 S-acylation complex. Preliminary phenotypic
analyses of AKR1 and YCK2 dependant phenotypes for an
AKR1 construct lacking the ankyrin repeats and carrying the
C
500S mutation were identical to akr1D null mutants indicating
that these are the only two functionalities of AKR1 affecting our
observations (data not shown). We therefore decided that assaying
this construct for its ability to S-acylate YCK2 was not required.
These data confirm that the DHHC cysteine is required for YCK2
S-acylation and demonstrate that the ankyrin repeats are not an
absolute requirement. However the ankyrin repeats do appear to
increase YCK2 S-acylation by an unknown mechanism that does
not require the ankyrin repeats and DHHC domain to be on the
same molecule.
The ankyrin repeats of AKR1 interact directly with Gbc
and are required to suppress Gb activity in STE4 over
expression assays
Data in Figure 2 indicates that the ankyrin repeats of AKR1 are
not an absolute requirement for AKR1 PAT activity but these
data do not suggest an alternative role for them. AKR1 has been
shown to negatively regulate the effect of Gbc on the mating
pathway in the absence of mating pheromone [1,4]. AKR1 also
interacts with STE18/Gcin yeast-2-hybrid assays [1]. Published
evidence does not support the hypothesis that AKR1 regulates
Gbc by S-acylation because, although Gbc requires S-acylation of
the STE18 Gc subunit for localisation to the plasma membrane
[20,21], previously published data demonstrated that two other
DHHC S-acyl transferases, ERF2 and SWF1, are responsible not
AKR1 [7].
Over expression of the Gbc dimer b subunit STE4 leads to cell
cycle arrest but high levels of AKR1 expression prevent this,
allowing growth to proceed [4]. Figure 3A shows that the S-acyl
transferase null AKR1 C
500S, presumably acting as a membrane
localised set of AKR1 ankyrin repeats, is able to suppress STE4
induced cell cycle arrest, but AKR1 DN is not. Expression of the
ankyrin repeats in a free soluble form does not suppress the effects
of STE4 overexpression (Figure 3A). These data suggest that Gbc
interaction with AKR1 and suppression of Gbc activity are
dependent upon the ankyrin repeats and their membrane
association through the transmembrane domains of AKR1 and
not on the DHHC S-acyl transferase/PAT domain of AKR1.
One hypothesis is that the ankyrin repeats of AKR1 inhibit Gbc
by physically sequestering the Gbc dimer. This would require a
stable complex to be formed containing the ankyrin repeats of
AKR1 and Gbc Using the split-ubiquitin dual membrane yeast-2-
hybrid system AKR1 and AKR1 C
500S were shown to interact
with STE18, the c subunit of the bc dimer (Figure 3B). This
interaction is entirely dependent on the ankyrin repeats of AKR1;
AKR1 DN does not interact with STE18 (Figure 3B). Importantly,
the ankyrin repeats of AKR1 expressed on their own and
anchored to the membrane interact just as effectively with
STE18 as full length AKR1 (Figure 3C).
These results show that the ankyrin repeats of AKR1 can bind
Gbcindependently of the rest of AKR1, providing that the ankyrin
repeats are membrane associated, and AKR1 that is unable to
catalyse S-acylation can still suppress Gbc activity.
The DHHC cysteine and ankyrin repeats of AKR1 are both
required for full complementation of akr1D defects, but
do not need to be on the same molecule
The data presented above indicate that, although AKR1
dependent S-acylation relies upon DHHC function, the ankyrin
repeats may serve to increase the efficiency of the S-acylation
reaction by unknown means and can bind Gbc independently of
the DHHC domain. In light of these findings we dissected the roles
and contribution of each domain, assessing the ability of AKR1
C
500S and AKR1DN to complement the known phenotypes of
akr1D mutants. Yeast cells lacking AKR1 are misshapen and
frequently show abnormal growth including failure to separate
after cytokinesis, elongated cells and branching at bud sites. This is
believed to be due to simultaneous activation of both the
vegetative and mating pathways due to poor suppression of basal
Gbc signalling and faulty YCK2 S-acylation [1,3,4]. During pilot
experiments akr1D yeast expressing a version of AKR1 lacking
Figure 2. S-acylation of over expressed GFP-YCK2 requires the
DHHC domain of AKR1. S-acylation of GFP-YCK2 is supported by
AKR1 or AKR1 DN but not by AKR1 C
500S. The presence of the AKR1
ankyrin repeats on the non-S-acyl transferase competent AKR1 C
500S
improves S-acylation of GFP-YCK2 when co-expressed with AKR1 DN. S-
acylation states were assayed by the biotin switch method, +indicates
presence of hydroxylamine, 2indicates absence of hydroxylamine. EX –
S-acylation state of GFP-YCK2, LC – loading control for GFP-YCK2.
doi:10.1371/journal.pone.0028799.g002
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difference in any of the phenotypes tested here compared to the
akr1D mutant (data not shown) indicating that AKR1 does not
contain any additional domains that affected our observations.
akr1D yeast expressing AKR1 C
500S do not show any restoration
of the morphological phenotypes and actually have a higher
proportion of cells that fail to separate after cytokinesis (multiple
bud phenotype, Figure 4A, Figure S3). This indicates that YCK2
function is not restored but cell cycle progression is not impaired.
akr1D yeast expressing AKR1 DN show significant increases in
the proportion of wild type morphology cells, a slight increase in
cells with a schmoo like morphology and a decrease in the number
of cells showing branching or pseudohyphal morphology com-
pared to akr1D cells (Figure 4A, Figure S3). This indicates that
YCK2 function is restored and that the majority of AKR1
function required to maintain correct cell shape is provided by the
DHHC domain. However, mating pathway suppression has not
occurred in these cells, which still have a higher tendency to
schmoo and go into cell cycle arrest than cells expressing full-
length AKR1. Co-expression of AKR1 C
500S and AKR1 DN fully
restores wild type morphology to akr1D cells (Figure 4A, Figure
S3). These data demonstrate that while both domains are required
to fully complement the growth and morphological defects
observed in akr1D mutants the two domains do not need to be
on the same molecule.
akr1D yeast cells display temperature sensitivity with mortality
increasing with elevated temperatures [4,5]. Yeast expressing
either the S-acyl transferase null AKR1 C
500S or the ankyrin-
repeatless AKR1 DN do not show restoration of this phenotype.
However, co-expression of AKR1 C
500S and AKR1 DN restores
temperature tolerance, again demonstrating that the DHHC
domain and ankyrin repeats of AKR1 are not required to be on
the same molecule for full restoration of akr1D phenotypes
(Figure 4B).
Defects in the vegetative morphology of akr1D mutants are due
in part to up regulation of mating pathway signalling in the
absence of mating pheromone without full repression of vegetative
pathways [1,4]. In wild type cells perception of mating pheromone
by STE3 leads to the activation of the STE20/STE11/STE7/
FUS3 MAPK cascade through Gbc ultimately switching yeast
from vegetative to mating state, activating downstream genes such
as FUS1 which are required for mating, and inducing cell cycle
arrest. In akr1D mutants basal Gbc signalling is not suppressed and
FUS1 is constitutively expressed at low levels [1,4]. AKR1 and
Figure 3. AKR1 interacts with Gbc through its ankyrin repeats.
(A) Over-expression of the Gb subunit STE4 from the GAL1 promoter of
pJB9 leads to cell cycle arrest and failure to grow on galactose medium
(Gal). All strains grew well on glucose medium (Glu). Over expression of
AKR1 or AKR1 C
500S from high copy number vectors suppresses STE4
over expression induced cell cycle arrest whereas AKR1 DN or non-
membrane associated AKR1 ankyrin repeats (AKR1 ANKS) do not. (B)
Yeast-2-hybrid analysis of the interaction between AKR1 variants and
the Gc subunit STE18. AKR1 and AKR1 C
500S both suppressed the ade2D
red phenotype and produced strong growth on medium selecting for
activation of HIS3 and ADE2 reporter genes as a result of interaction
with STE18 whereas AKR1 DN did not. –LW: control medium, -LWHA:
selection medium for reporter activation. +denotes pAI (positive control
vector), 2denotes pDL2 (negative control vector), pPR3N – empty prey
vector control, STE18 – pPR3N expressing STE18. (C) Yeast-2-hybrid
assay demonstrating direct interaction between the ankyrin repeats of
AKR1 and the Gc subunit STE18. The AKR1 ankyrin repeats suppress the
ade2D red phenotype and produce strong growth on medium selecting
for activation of HIS3 and ADE2 reporter genes as a result of the AKR1
ankyrin repeats interacting with STE18. Controls are the same as for part
B.
doi:10.1371/journal.pone.0028799.g003
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500S are capable of suppressing basal FUS1 transcription
as measured by FUS1 mRNA levels (Figure 4C) although AKR1
C
500S does not repress FUS1 transcription quite as well as AKR1.
This may be due to the reduced levels of AKR1 C
500S in the cell
compared to AKR1 described earlier (Figure 1C) or DHHC
function being required for full suppression. akr1D mutants
expressing AKR1 DN show levels of FUS1 activation that are
greater than cells expressing AKR1 or AKR1 C
500S but lower
than in akr1D mutants, suggesting that the ankyrin repeats, rather
than the DHHC domain, are the main suppressors of FUS1
transcription by AKR1. Co-expression of AKR1 DN and AKR1
C
500S suppresses FUS1 to similar levels as full length AKR1.
These data are supported by growth rate analysis that indicates
that co-expression of AKR1 C
500S and AKR1 DNi nakr1Dcells
restores WT growth rates. AKR1 C
500S expressed on its own in
akr1Dcells grows slightly better than akr1D, presumably because
Gbc induced cell cycle arrest is suppressed by the ankyrin repeats
even though cell division and correct morphogenesis is still
impaired. AKR1 DN expressing akr1Dcultures grow more slowly
than akr1D and do not reach the same levels of culture saturation
(Figure S4). This is likely due to restoration of YCK2 and other S-
acylation dependant functions resulting in largely normal
morphological processes but with an inability to suppress Gbc
induced cell cycle arrest leading to a slow growth phenotype. All of
these data combined indicate that suppression of the mating
pathway in the absence of mating pheromone is achieved by both
the ankyrin repeats and DHHC domain of AKR1 acting in
concert by independent and distinct mechanisms within the same
network.
Discussion
AKR1 suppresses basal Gbc-mediated mating pathway signal-
ling in the absence of mating pheromone and promotes the
maintenance of the vegetative state [1,4]. We found that both the
ankyrin repeats and DHHC domain of AKR1 contribute to this
suppression. For many of the phenotypes we tested both the
ankyrin repeat and DHHC domains are required, but they do not
need to be on the same molecule indicating that AKR1 is a bi-
Figure 4. AKR1 requires both the DHHC domain and ankyrin
repeats for rescue of phenotypic and mating pathway
activation defects, but they do not need to be on the same
molecule. (A) akr1D mutants show a reduction in WT morphology
cells (black bars) and an increase in the proportion of cells with schmoo-
like (grey bars) or multiple bud phenotypes (white bars). Introduction of
AKR C
500St oakr1D cells (akr1D+C
500S) suppresses the schmooing
phenotype but increases the number of cells showing a multiple bud
phenotype. Introduction of AKR1 DNt oakr1D cells (akr1D+DN) fails to
suppress the schmooing phenotype but does reduce the number of
cells that show a multiple bud phenotype. Co-expression of AKR1 C
500S
and AKR1 DN( akr1D+C
500S+DN) in akr1D cells restores all morpholog-
ical phenotypes to that observed for expression of full length WT AKR1
(akr1D+AKR1). The data represents the average of 3 independent
experiments with .220 cells counted per genotype per experiment.
Representative images of cultures used to generate these data are
shown in Figure S3. Error bars represent 1 standard deviation. (B) akr1D
mutants show a temperature sensitive phenotype with growth
occurring at 25uC but not at 37uC. Introduction of AKR C
500S
(akr1D+C
500S) or AKR1 DNt oakr1D cells (akr1D+DN) fails to suppress
the temperature sensitive phenotype. Co-expression of AKR1 C
500S and
AKR1 DN( akr1D C
500S+DN) in akr1Dcells restores temperature
resistance as effectively as full length WT AKR1 (akr1D AKR1). (C)
akr1Dmutants show low level induction of the mating pathway in the
absence of mating pheromone as measured by real time PCR of FUS1
mRNA. Introduction of AKR1 C
500St oakr1Dcells suppresses FUS1
induction significantly compared to akr1D while AKR1 DN only partly
suppresses FUS1 induction. Error bars represent a 95% confidence
interval calculated from 3 technical replicates. Data are representative
of 3 independent experiments.
doi:10.1371/journal.pone.0028799.g004
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within the same pathway or network. AKR1 has previously been
shown to be a PAT, and we show that part of the function of the
ankyrin repeats is to increase S-acylation of YCK2 by an unknown
mechanism. Interestingly the ankyrin repeats are not required on
the same molecule as the DHHC PAT function to promote YCK2
S-acylation indicating that it may not be a direct effect. Our data
suggest that the AKR1 ankyrin repeats continue to affect aspects of
Gbcmediated mating pathway signalling even when there is no
detectable AKR1 PAT activity in the cell (Figure 3, 4). We also
show that AKR1 molecules are S-acylated at locations other than
the DHHC cysteine, and that this increases the abundance of
AKR1 in the cell. Our results prompt a reassessment of AKR1 and
PAT research to date, especially recent attempts to study S-
acylation enzymology and kinetics, and suggest several new lines of
enquiry for future work on this and related proteins in other
eukaryotic cells.
AKR1 increases its own S-acylation at sites outside the
DHHC motif
AKR1 molecules are able to increase each other’s S-acylation at
sites outside of the DHHC motif and this appears to promote the
stability or reduce the turnover of AKR1 (Figure 1A, 1B, 1C). S-
acylation of DHHC PATs outside of the DHHC cysteine has been
reported for DHHC-5, -6 and -8, from humans in a proteomics
study [22] but it is not know if their S-acylation occurs in-cis or in-
trans either by themselves or other PATs. The motif identified as
being S-acylated in these proteins does not exist in AKR1 or other
yeast DHHC PATs indicating that the S-acylation event identified
in our study occurs at a novel site. The simplest explanation for
our data is that AKR1 molecules S-acylate each other directly
using intermolecular rather than intramolecular transfer of S-acyl
groups. This conclusion is supported by evidence that molecules of
AKR1 with an intact DHHC domain cysteine are an absolute
requirement for AKR1 S-acylation to occur outside of the DHHC
domain (Figure 1A, 1B). However, stable interaction between
AKR1 monomers is not detectable by co-immunoprecipitation
[12] or yeast-2-hybrid (Figure S2) assays and the possibility that
AKR1 monomers somehow target each other for S-acylation by
other S-acyl transferases cannot be completely ruled out, although
interpretation of in-vitro data on auto-S-acylation of the DHHC
PAT ERF2 [18] in light of our findings suggests that this is
unlikely.
The ability to purify an S-acylated form of a PAT has been used
to propose that they form a stable intermediate with a covalently
bound S-acyl group before transferring the S-acyl group to the
substrate and that the DHHC cysteine is likely to be the catalytic
site [5,13,16,17,18,19,23]. These assays have been largely
interpreted assuming that S-acylation only occurs on the DHHC
cysteine. Our discovery that AKR1 is S-acylated at sites other than
the DHHC cysteine potentially casts doubts on some of the
conclusions drawn from these assays. This additional S-acylation
could mask the binding of S-acyl groups to the active site and
transferral to substrates and provides a possible alternative S-
acylation substrate for the PAT that could interfere with attempts
to investigate the kinetics or mechanism of the S-acylation
reaction.
These ideas may offer a solution to an unexplained phenom-
enon observed in a recent study examining the kinetics of S-
acylation of RAS2 by ERF2, another yeast DHHC PAT [18].
ERF2 auto-S-acylates in the presence of palmitoyl-CoA in two
distinct stages; a rapid initial phase, lasting only a few seconds at
room temperature, followed by a prolonged steady state phase.
The steady state phase is a cycle of auto-S-acylation of ERF2,
releasing free CoASH as a result of ERF2 covalently binding
palmitate, followed by hydrolytic turnover of the palmitoyl group
to release free palmitate. This cycle proceeds at a steady rate; in
the presence of excess palmitoyl-CoA, CoASH release and
palmitate hydrolysis occurs in a 1:1 ratio indicating that for every
palmitate hydrolysed a new one is bound. This cycle cannot
however explain the initial rapid phase where CoASH is released,
indicating S-acylation has occurred, but palmitate is not
hydrolysed from ERF2 (no turnover). Palmitate hydrolysis does
not follow the same initial rapid kinetics as CoASH release but
proceeds at the same rate as the later stage steady state CoASH
release throughout [18], indicating that much of the initial
palmitate bound by ERF2 is not hydrolysed and turned over.
These intriguing kinetic data are commented on by the authors
[24] but not fully explained. Our results suggest a plausible
explanation where the rapid initial CoASH release and increase in
S-acylated ERF2 and lack of palmitate hydrolysis are due not only
to DHHC domain auto-S-acylation, but also to stable addition of
palmitate to ERF2 by other ERF2 molecules at a site other than
the DHHC cysteine, in a manner consistent with our results
reported here with AKR1. This extension of the previous
hypothesis could be tested initially by determining whether
ERF2 carrying the C
203S mutation is S-acylated in WT but not
in erf2D cells. This will give an indication as to whether ERF2
influences its own S-acylation at non-DHHC sites. If this proves to
be the case then identification and mutation of the site followed by
repeating the ‘‘auto-S-acylation’’ kinetic analysis of ERF2 and
ERF2 lacking the non-DHHC S-acylation site would allow
comparison of kinetics and testing as to whether S-acylation in
trans of ERF2 affects or obscures the true kinetics of WT ERF2.
These data may then help explain the intriguing results reported
previously [24].
Our observations should not greatly affect the data obtained
from the steady state kinetics observed in these studies but may
complicate observations at early time points. Measurements using
CoASH release would include that released during the S-acylation
of ERF2 at the non-DHHC site and therefore lead to an
overestimation of the initial rate at the DHHC site. They also
indicate that over estimation of the steady state levels of binding of
palmitoyl-CoA is likely as the covalently bound non-transferable
palmitoyl-CoA added by ERF2 to other ERF2 molecules during
the initial stages of the reaction would be included in the count.
These data indicate the need for careful consideration of this new
factor in experimental set up and design. The use of thioester
cleaving reducing agents that will liberate free S-acylatable
sulfhydryls during purification of the PAT may need to be limited
or taken into consideration during assays. We suggest that
reactions to measure kinetics should be initiated by the addition
of substrate rather than palmitoyl-CoA or that PAT that has been
pre-treated with cold palmitoyl-CoA to eliminate signal from non-
catalytic S-acylation sites should be used.
The S-acylation of AKR1 and ERF2 outside of the DHHC
cysteine might restrict their in-vivo sub-cellular and membrane
microdomain distribution, as has been described for other S-
acylated proteins [25,26,27,28]. If so then abnormally S-acylated
AKR1 could have an undefined or aberrant distribution within
cellular membrane compartments and membrane microdomains
causing a decrease in interaction efficiency with partner proteins
such as Gbc or S-acylation targets resident in specific membrane
microdomains. Alternatively, S-acylation of AKR1 could reduce
its degradation and turnover, as has been proposed for TLG1
[29].
The data presented here are also compatible with the idea that
each S-acylation reaction, such as YCK2 S-acylation by AKR1,
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itself and finally on YCK2. Our data indicate that S-acyl groups
are transferred from AKR1 to a non-DHHC cysteine of AKR1 in-
trans in a DHHC domain dependant manner. This version of
AKR1, S-acylated at the non-DHHC site, could be the active
transferase for substrate S-acylation. It is still not clear whether the
DHHC cysteine is actually the active site.
The ankyrin repeats of AKR1 contribute to the regulation
of Gbc signalling by two mechanisms
akr1D cells show reduced constitutive ligand independent STE3
endocytosis [2], and defective YCK2 S-acylation [5] resulting in
increased basal mating pathway induction through Gbc [1,4].
akr1D cells also show defective cytokinesis resulting in multiple
budding events that frequently fail to separate [1] leading to multi-
nucleate cell masses [4]. Interestingly akr1D mutants do not show
defects in mating pathway induction after treatment with mating
pheromones indicating that AKR1 acts to suppress mating
pathway activation but only in the absence of pheromone [1,4].
We show that the ankyrin repeats of AKR1 contribute to AKR1
function in at least two ways. Firstly, they promote the S-acylation
of YCK2 by an unknown mechanism (Figure 2) that does not
require the ankyrin repeats and DHHC domain to be on the same
molecule. These data, coupled with data indicating that AKR1
does not interact with itself, suggest that the influence of the
ankyrin repeats on YCK2 S-acylation is likely to be indirect, rather
than directly affecting the S-acylation reaction itself. Secondly, we
show that the ankyrin repeats have strong effects on Gbc signalling
in the absence of detectable AKR1 S-acylation activity. Data in
Figures 1 A and B and Figure 2 confirm previously published
results that AKR1 C
500S has no detectable S-acylation activity [5]
and that it essentially functions as a membrane localised form of
the AKR1 ankyrin repeats, yet we show that reintroduction of this
protein into akr1D cells suppresses the majority of FUS1 up
regulation observed in akr1D cells as a result of mating pathway
activation (Figure 4C). AKR1 C
500S can also counter the effects of
STE4 over expression to permit growth (Figure 3A) and partially
rescue the temperature-sensitivity of akr1D cells (Figure 4B).
Furthermore, AKR1 DN cannot suppress STE4 over expression
induced cell cycle arrest (Figure 3A), schmooing (Figure 4A), or the
temperature-sensitivity of akr1D (Figure 4B). We also demonstrate
that the ankyrin repeats on their own, when artificially anchored
to the membrane, interact with STE18 in yeast-2-hybrid assays
(Figure 3B, C). Interestingly the ankyrin repeats, when expressed
in a soluble form, do not suppress the effects of STE4 over
expression (Figure 3A). Taken together, these results suggest that
the ankyrin repeats of AKR1 play a significant role in the
regulation of Gbcactivity that is independent of the S-acylation
activity of AKR1. These data also indicate that the ankyrin repeats
require membrane association, either through the transmembrane
domains of AKR1 or by artificial recruitment in the DUALmem-
brane yeast-2-hybrid system, to have these effects. This is perhaps
unsurprising given that Gbc is also membrane associated through
prenylation and S-acylation of STE18/Gc [20].
Overall contribution of AKR1 to the suppression of Gbc
induced mating pathway activation in the absence of
pheromone
The interpretation of literature to date suggests that AKR1 is a
PAT [5] and that it somehow suppresses Gbc induced mating
pathway activation [1,2,4], presumably via its PAT activity and
possibly through YCK1 and 2. Here we present evidence that this
view should be revised to incorporate ankyrin repeat function that
does not require the AKR1 DHHC domain. Given that both the
ankyrin repeats and DHHC domain affect the same overall
processes and pathways it is perhaps not surprising that each is
able to either fully or partially substitute for AKR1 but one is
usually more effective than the other (Figures 1, 2, 3 and 4).
Importantly, co-expression of AKR1 C
500S and AKR1 DN
restores all of the phenotypes tested even though the ankyrin
repeats and S-acylation domain are on different molecules
(Figure 4A, 4B, 4C). This indicates that although direct interaction
of AKR1 monomers has not been shown to occur ([12], Figure S2)
the functions of each domain are both required at the same time to
adequately suppress the basal activation of the mating pathway.
YCK2 coordinates growth, septin formation, schmoo polariza-
tion and cell division during the cell cycle. To correctly perform
these functions YCK2 cycles between different subcellular
locations depending on the stage of the cell cycle [30] and
requires S-acylation by AKR1 for this to occur [5,10]. Our data
support the previous hypotheses that the gross phenotypes
observed in akr1D mutants, which are superficially similar to
yck1D yck2D double mutants [9], are the result of simultaneous
vegetative and mating pathway activation and an inability to
coordinate correct cell division and organise cell polarity [1,4]. We
propose that in akr1D cells YCK2 and other S-acylated targets of
AKR1 are functionally impaired as they are not S-acylated and
therefore unable to coordinate the functions required for correct
cellular function and basal Gbc signalling is not suppressed by the
AKR1 ankyrin repeats and partial cell cycle arrest occurs. These
defects in the two different biochemical functions of AKR1 allow
both mating and vegetative pathways to be concurrently, but
incorrectly, active causing the gross phenotype of akr1D cells.
Analysis of growth rates indicates that AKR1 DN actually grows
more slowly (Figure S4) and shows a higher rate of schmoo
formation (Figure 4A) than akr1D. This is likely due to restoration
of YCK2 function (e.g. Figure 2). We speculate that restoration of
YCK2 function in AKR1 DN cells induces cell cycle arrest to a
greater degree than in akr1D as the cell is able to correctly respond
to vegetative and mating morphogenic signalling, such as
controlling the correct number of budding/schmoo events and
co-ordinating cell division, but without the ability provided by the
ankyrin repeats to suppress basal Gbcsignalling,resulting in cell
cycle arrest. A speculative model that can account for our new
data on AKR1 function whilst placing it in the context of earlier
work [1,2,4,5] is shown in Figure 5.
Potential function of AKR1-like proteins
Given our data the origin of AKR1 like proteins may be a result
of the need for close temporal coordination between two
overlapping functions acting within the same overall network.
AKR1 like proteins containing both DHHC domains and ankyrin
repeats have been identified in eukaryotes from all three kingdoms
[1,4,13,31,32]. This indicates that the origin of DHHC domain
proteins containing ankyrin repeats is ancient and may have
conserved purpose. This is supported by evidence that both
human HIP14 [31] and Arabidopsis TIP1 [13] homologues of
AKR1 are able to restore defects observed in akr1D mutants that
are associated with loss of both ankyrin repeat and PAT function.
Both HIP14 and TIP1 are able to act as S-acyl transferases
[13,14,15] but these data also suggest that the fundamental roles of
the ankyrin repeats have also been conserved in these proteins.
A similar situation to that observed in yeast, where AKR1 acts
to suppress mating pathway activation by the STE20 MAPKKKK
in favour of vegetative growth pathway activation by the CLA4
MAPKKKK (Figure 5), occurs in mammals where the two
opposing JNK and p38 MAPK pathways are regulated and
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HIP14 is able to increase activation of the mammalian JNK MAPK
pathway and the ankyrin repeats are required for this [32]. UV
stress or over expression of the appropriate UV responsive human
Gbc complex Gb1c2 in COS-1 cells activates the p38 MAPK
cascade which directly suppresses JNK activation [33]. Sequestra-
tionofGb1c2byoverexpressionofHIP14could conceivablyleadto
increased activation of the JNK pathway by preventing the
activation of the p38 MAPK pathway by Gb1c2. Available data
are consistent with a model where the ankyrin repeats of AKR1 like
proteinssequesterGbcdimersreleased from unstimulatedreceptors
(i.e. basal or leaky signalling in the receptor off state) or from
recycling of signalling components after signalling events. This
model would essentially put the ankyrin repeats of AKR1-like
proteins as threshold or gating switches that suppress basal Gbc
signalling in the absence of receptor stimulation. After activation of
GPCRs the level of Gbc released from activated Gabc heterotri-
mers in the cell would exceed AKR1-like proteins’ buffering ability
and the downstream signalling pathway would be activated.
The human AKR1 homologue HIP14 is responsible for the
majority of Huntingtin (Htt) S-acylation activity in mammalian
cells [15]. Recent data indicates that addition of the ankyrin
repeats of HIP14 to another PAT, DHHC-3, in neuronal cells
increases the efficiency of Htt S-acylation by over expressed
DHHC-3 [34]. PATs have low substrate specificity and are
promiscuous enzymes, especially when over expressed [35,36],
and a recent report suggests that mammalian PAT specificity for
peripheral membrane proteins, such as Htt, is minimal or entirely
absent [36]. DHHC-3 is reported to have particularly wide
substrate specificity and is capable of S-acylating Htt even in the
absence of prosthetic HIP14 ankyrin repeats [34]. Whether the
observed increase in S-acylation is a result of direct binding of Htt
by the ankyrin repeats followed by S-acylation or altered
localisation or stability of the fusion has not been addressed.
The observed data may also be explained by the ankyrin repeats
recruiting the low specificity S-acylation activity of over expressed
DHHC-3 to a usually HIP14 containing Htt S-acylation complex.
It will be interesting to discover whether AKR1-like proteins in
other eukaryotes have multiple functions that act within a single
overall network, as appears to be the case for AKR1 in the yeast
mating pathway. Studies in other eukaryotes would help elucidate
whether the AKR1 state of having both functions act within the
same pathway is derived or ancestral.
Materials and Methods
Strains and plasmids
6xHIS/3xHA/FLAG epitope tagged versions of AKR1 ex-
pressed from its native promoter (pRS316, pRS315 [37] and
pESC 2morigin based) were created by PCR based recombination
in yeast using pND1434 [5] as the base AKR1 template. AKR1
C
500S has been described previously [5]. AKR1 DN carries a
deletion of amino acids 3–302 inclusive. Expression of free AKR1
ankyrin repeats involved deletion of amino acids 303–755
inclusive. Recombinant plasmids were screened by colony PCR
and sequenced before use. Over expression of STE4 was achieved
by cloning STE4 downstream of the GAL1 promoter of pJB9.
Expression of GFP-YCK2 from the GAL1 promoter was achieved
using pJB1 [30]. Vectors for yeast-2-hybrid were produced by
cloning AKR1 variants lacking start and stop codons in frame into
the SfiI sites of pBT3-STE. AKR1 ankyrin repeats (covering
amino acids 2–311) for yeast-2-hybrid were cloned into the Sfi1
sites of pBT3-OST4. pBT3-OST4 was created by replacing the
STE2 leader peptide of pBT3-STE with the entire OST4 ORF
lacking start and stop codons by homologous recombination in
yeast. STE18 was cloned, lacking the start codon, in frame with
the SfiI sites of pPR3-N.
All yeast strains used for characterising AKR1 cellular functions
were isogenic with BY-series strains used for the EUROscarf
deletion program [38] WT BY4742 genotype (accession number -
Y10000) - MATa; his3D1; leu2D0; lys2D0; ura3D0. akr1D geno-
type (accession number - Y13623) - MATa; his3D1; leu2D0;
lys2D0; ura3D0; YDR264c::KanMX4. Yeast-2-Hybrid analysis was
performed in strain NMY51 (MATa his3D200 trp1-901 leu2-3,112
Figure 5. Speculative model of AKR1 function suggested by
our results and the literature. Our results are consistent with a
model where the ankyrin repeats suppress aspects of Gbc-induced
mating pathway activation independently of the DHHC domain. In the
absence of mating pheromone the ankyrin repeats suppress basal Gbc
signalling through the STE20 MAPK pathway, possibly by directly
binding (see results in Figure 3) and sequestering Gbc or a Gbc
containing complex released by basal STE3 activity away from
downstream mating pathway components The DHHC domain sup-
presses inappropriate mating pathway activation by ensuring STE3
levels are kept low via the S-acylation of YCK2, which in turn would
phosphorylate STE3 at the plasma membrane leading to STE3
endocytosis. These processes would both help to maintain low levels
of basal Gbc signalling and promote vegetative growth. This model
suggests the following explanations for the phenotypes that we have
observed. The low level mating pathway activation in AKR1DN
expressing cells could be due to free Gbc released by basal STE3
activity partially activating the mating pathway in the absence of AKR1
ankyrin repeats (which would otherwise suppress Gbc activity). AKR1
C
500S, unable to S-acylate YCK2, would lead to a failure in constitutive
endocytosis of STE3 [2,3], and the resultant elevated levels of STE3
would lead to elevated basal Gbc release [2], exceeding the buffering
potential of the ankyrin repeats. This would explain the slightly poorer
performance of AKR1 C
500S in suppressing FUS1 induction (Figure 4C).
Domains of AKR1 and proteins with roles predominantly in vegetative
growth are represented in white while those with roles predominantly
in mating are represented in grey. Broken lines represent S-acylation
activity of AKR1. Arrowed lines represent positive effects on function,
barred lines represent negative effects on function. AKR1 DHHC – DHHC
domain of AKR1, AKR1 ANK – ankyrin repeats of AKR1.
doi:10.1371/journal.pone.0028799.g005
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obtained from DUALsystems biotech. Yeast transformation was
performed as described [39]. Yeast were cultured using standard
laboratory techniques and media.
Growth assays
For temperature sensitivity assays strains were grown to mid log
phase (O.D.600 0.6–0.8) in SD-LU, and serial dilutions from 10
6 to
10
4 cells per ml prepared in SD-LU and 10 ml aliquots plated onto
SD-LU plates. Plates were incubated at 25uC and 37uC for 48–
60 hours. Strains for suppressing STE4 induced growth arrest
were grown to mid-log phase in SD-LU, washed once in distilled
water and resuspended in 0.9% NaCl. Serial dilutions from 10
6 to
10
4 cells per ml were prepared and 10 ml aliquots spotted onto
YPD and YPGalRaf plates and incubated at 25uC for 36 hours
(YPD) or 48 Hours (YPGalRaf).
S-acylation assay
S-acylation assays using a modification of the biotin switch
method [40] were performed as described [41]. Briefly, samples
were incubated with N-ethylmaleimide to block free sulfhydryls.
Samples were then incubated with biotin-HPDP (Thermo
Scientific) in the presence or absence of the thioester cleaving
reagent hydroxylamine. Samples were purified using Neutravidin
resin and eluted into 26SDS sample buffer. Protein S-acylation
state was determined using antibodies against the protein of
interest as a function of recovery by the Neutravidin beads.
Induction of YCK2:GFP for use in S-acylation assays was
performed by adding galactose to mid-log phase cultures in
selective synthetic raffinose medium. After 90 minutes of induc-
tion, glucose was added to 2% and cultures incubated for a further
90 minutes before harvesting.
Western blotting
Protein extracts were prepared from yeast cells using standard
methods [42] or as described for S-acylation assays [41]. Western
blots to detect epitope tagged AKR1 variants were performed using
anti-HA polyclonal antibody (Santa Cruz Biotechnologies, sc-805)
diluted 1:200 in 5% skimmed milk powder, 0.05% Tween-20, TBS
(5%MTBST). YCK2-GFP was detected using anti-GFP polyclonal
antibody (Santa Cruz Biotechnologies, sc-8334) diluted 1:200 in
5%MTBST. Primary antibodies were detected using goat anti-
rabbit IgG-HRP conjugate (Santa Cruz Biotechnologies, sc-2004)
diluted 1:5000 in 5%MTBST. Blots were exposed to Hyperfilm
ECL(GEHealthcare)usingECLadvancereagents(GEHealthcare).
Yeast-2-hybrid
Interaction analysis was performed using the Dual membrane
yeast-2-hybrid assay (Dualsystems Biotech). To assay interactions
yeast were grown to mid log phase, collected by centrifugation,
washed once in distilled water and resuspended in 0.9% NaCl.
Serial dilutions from 10
6 to 10
4 cells per ml were prepared and
10 ml aliquots were spotted onto synthetic dextrose media lacking
the appropriate amino acids for plasmid selection (SD-LW,
control) and for reporter gene expression (SD-LWHA+1m M3 -
aminotriazole, experimental) and incubated at 25uC until strong
growth was observed (48–60 hours).
Real time PCR
Total cellular DNA free RNA was extracted using a RNeasy
mini kit with on column DNAseI digestion (Qiagen) from mid-log
phase yeast cells grown in selective medium. FUS1 expression
levels were standardised to IPP1 expression as IPP1 expression is
extremely stable over a wide range of conditions [43]. 2 mgo f
RNA was reverse transcribed using a High Capacity Reverse
Transcriptase kit with random hexamers (Applied Biosystems).
Quantitative real time PCR was performed on a 7300 Real Time
PCR system (Applied Biosystems) using FastStart Universal SYBR
Green Master Mix with ROX as a passive control (Roche). PCR
products were validated using melt curve analysis. Primers used
were FUS1f - GGTGTGATATTGTCATCAAGTTGCA,
FUS1r - TGATGTTGGTAACGGCACATG, IPP1f - CAAG-
GGTATTGATTTGACCAATGTT, IPP1r - GAGGCAGCC-
TTGGAGTAGGTT.
Supporting Information
Figure S1 Cartoon structure of AKR1 and AKR1 vari-
ants used in this study. ARPS – 6 ankyrin repeats, DHYC – S-
acyl transferase domain, DHYS – C
500S mutant version of the
AKR1 DHHC domain unable to act as a PAT. Solid black boxes
represent transmembrane spans.
(TIF)
Figure S2 A. AKR1 variants do not interact with each other in
pairwise interaction assays. AKR1 variants in pBT3-STE (bait)
were screened for interaction with AKR1 variants in pBT3-STE,
pAI positive control vector (+), pDL2 negative control vector (2)
and empty prey vector (pPR3-STE). All strains grew on media
selective for plasmids (-LW) but only pAI interaction with AKR1
variants supported growth on selective media (-LWHA) indicating
that the bait constructs are functional. B. AKR1 variant prey
constructs are expressed in AKR1 variant bait backgrounds. A –
pPR3-STE AKR1, C - pPR3-STE AKR1 C
500S, N - pPR3-STE
AKR1 DN. Bait constructs are indicated at the bottom of the
figure. AKR1 and AKR1 C
500S are indicated by the upper arrow
and AKR1 DN by the lower arrow.
(TIF)
Figure S3 Representative images of akr1D cultures
expressing AKR1, AKR1 C
500S, AKR1 DN and AKR1
C
500S+AKR1 DN used to generate data for Figure 1A.
Scale bar represents 10 mm. akr1D cells are large, highly branched,
and multinucleate. akr1D cells co-expressing AKR1 or AKR1
C
500S+AKR1DN have wild typephenotypes. akr1D cells expressing
AKR1 C
500S alone are less likely to schmoo, but still produce
multiple buds. akr1D cells expressing AKR1 DN alone have fewer
multiple buds than akr1D cells but schmoo more than wild type.
(TIF)
Figure S4 Typical growth curves for the strains used in
this study. Cultures were grown in synthetic dropout media (SD-
LU) at 25uC with shaking to an OD600 of 0.8–1.2 and inoculated
into SD-LU to an OD600 of 0.15. Cultures were grown at 25uC
with shaking and monitored for 36 hours with OD600 measure-
ments taken every hour. All strains expressing AKR1 variants are
in the akr1D background.
(TIF)
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